How the product works:
Axitinib is a selective tyrosine kinase inhibitor that targets VEGF receptors (VEGFR-1, 2, and 3), thereby blocking tumour angiogenesis and growth.
Recommended for:
Advanced or metastatic renal cell carcinoma
Take orally twice a day, with or without food. Dosage and duration are determined by the treating physician based on response and tolerance.
Contraindications:
Side Effects: